Open Access

EZH2-mediated epigenetic repression of DNA repair in promoting breast tumor initiating cells

Breast Cancer Research201113:309

https://doi.org/10.1186/bcr2871

Published: 25 May 2011

Abstract

Members of the Polycomb-group (PcG) family of proteins, including EZH2 (enhancer of zeste homolog 2), are involved in establishing epigenetic silencing of developmental genes in adult and embryonic stem cells, and their deregulation has been implicated in cancer. In a recent report, EZH2-mediated epigenetic repression of DNA damage repair in breast tumor initiating cells (BTICs) was identified as a mechanism that could promote expansion of BTICs, and may contribute to cancer progression.

Background

EZH2 (enhancer of zeste homolog 2) is a member of the Polycomb-group (PcG) family and encodes a histone methyltransferase that is the catalytic component of the polycomb repressive complex (PCR)2 [1]. The PRC2 complex has a role in establishing methylation marks on histone H3 (triMe-K27 H3) to initiate chromatin condensation and silencing of genes involved in developmental processes [2, 3]. PcG proteins are known to be essential in maintaining self-renewal and pluripotency of stem cells [4], and their deregulation has been linked to cancer [5].

The cancer stem cell (CSC) hypothesis proposes that a limited subpopulation of cancer cells has self-renewal capacity and is responsible for tumor growth [6]. According to the CSC hypothesis, progression towards aggressive behavior can ultimately be traced to changes that occur in the CSCs, or tumor initiating cells (TICs). However, experimental data on the molecular changes and the mechanism by which they could occur have been lacking. In breast cancer, stem cell-like properties associate with expression of CD44, and negativity/low CD24, that is CD44+/CD24-/low [7]. Recently, Chang and colleagues [8] studied EZH2 in CD44+/CD24-/low cells, or breast tumor initiating cells (BTICs), and described an important link to genomic instability, activation of RAF1-β-catenin signaling, and expansion of the BTIC population.

The article

Chang and colleagues [8] demonstrate that increased EZH2 in CD44+/CD24-/low cells correlates with their increased abundance, that is, the proportion of CD44+/CD24-/low cells. Increased EZH2 in CD44+/CD24-/low cells was correlated with decreased RAD51 levels. Using chromatin immunoprecipitation (ChIP), the authors show that EZH2, and other PRC1/PRC2 proteins, are recruited to a putative Ploycomb response element on the RAD51 promoter. Here, hypoxia in the microenvironment was identified as a potential cause of EZH2 upregulation. The RAD51 gene has a well established role in DNA repair through homologous recombination and, accordingly, EZH2-mediated epigenetic repression of RAD51 associates with accumulation of DNA damage and chromosome abnormalities.

Using protein arrays, the authors identified increased expression of the RAF1 gene as a potential change associated with EZH2-induced genomic instability. Importantly, this association was found to be a consequence of acquired DNA copy number gains over the RAF1 gene at 3p25.2, resulting in activation of ERK and β-catenin, shown to confer survival and proliferative advantages for CD44+/CD24-/low cells. Importantly, inhibition of RAF1-MEK-ERK-β-catenin activation by small molecule inhibitors (AZD6244, Sorafenib) leads to effective elimination of CD44+/CD24-/low cells - that is, BTICs - suggesting potential implications with respect to clinical management of the disease.

Viewpoint

The most important insight from Chang and colleagues [8] is the observation that genomic instability induced by EZH2-mediated epigenetic repression of DNA repair, that is, RAD51, results in expansion of the BTIC population. Further, the order in which these changes occur did not influence the eventual outcome - that is, over-expression of EZH2 has the same effect as knock-down of RAD51. In this context, RAF1 amplification was described as a recurrent oncogenic consequence of down-regulated DNA repair leading to activation of ERK and β-catenin and the consequent promotion of the BTIC population. In breast cancer, EZH2 overexpression has previously been linked to aggressive and poorly differentiated carcinomas [9], and downregulated DNA repair [10]. The insights provided by Chang and colleagues relate to the identification of EZH2 in augmenting BTICs through epigenetic repression of DNA repair, leading to aggressive disease. These results are consistent with clonal evolution of CSCs, that is, the notion that aggressive secondary CSCs can arise from the primary population of CSCs. The clinical relevance relates to potential benefits from RAF1/MEK/ERK inhibitors in the treatment of breast cancer patients, and in preventing disease progression. Further, poly ADP ribose polymerase (PARP) inhibitors are highly effective in targeting cancer cells with homologous recombination defects and therefore hold unexplored potential in this regard, that is, in targeting secondary CSCs [11].

Although somatic mutations in DNA repair genes are rare in sporadic cancers, it is well established that susceptibility to cancer is commonly linked to inherited mutations in DNA repair genes, for example, BRCA1, BRCA2, PALB2, WRN and MLH1 [12]. This has led some to speculate that defects in DNA repair genes cannot explain instability in sporadic cancers [12], whereas others have emphasized epigenetic mechanisms [13]. Chang and colleagues [8] describe results suggesting a causative link between epigenetic inactivation of DNA repair, the emergence of genomic instability, and cancer progression. In breast cancer, epigenetic inactivation of the BRCA1 gene occurs through CpG island hypermethylation [14, 15]. BRCA1 is essential in DNA repair of double-strand breaks, with RAD51 as a crucial partner for error-free repair by homologous recombination [16]. Recently, Lim and colleagues [17] demonstrated that BRCA1 defective breast cancers represent an expanded population of luminal progenitor cells. This is consistent with the results described in Chang and colleagues [8], demonstrating DNA repair defects and expansion of tumor cells with progenitor/stem-cell characteristics. In conclusion, an important task in future research will be to explore the relationship between epigenetic repression of DNA repair, the induction of genomic instability, and markers of CSCs.

Abbreviations

BTIC: 

breast tumor initiating cell

CSC: 

cancer stem cell

PcG: 

Polycomb-group

PCR: 

polycomb repressive complex.

Declarations

Authors’ Affiliations

(1)
Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute, 08908 L'Hospitalet
(2)
Institucio Catalana de Recerca i Estudis Avançats

References

  1. Simon JA, Lange CA: Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008, 647: 21-29.View ArticlePubMedGoogle Scholar
  2. Pasini D, Bracken AP, Hansen JB, Capillo M, Helin K: The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol Cell Biol. 2007, 27: 3769-3779. 10.1128/MCB.01432-06.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, Johnstone SE, Cole MF, Isono K, Koseki H, Fuchikami T, Abe K, Murray HL, Zucker JP, Yuan B, Bell GW, Herbolsheimer E, Hannett NM, Sun K, Odom DT, Otte AP, Volkert TL, Bartel DP, Melton DA, Gifford DK, Jaenisch R, Young RA: Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. 2006, 125: 301-313. 10.1016/j.cell.2006.02.043.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Rajasekhar VK, Begemann M: Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells. 2007, 25: 2498-2510. 10.1634/stemcells.2006-0608.View ArticlePubMedGoogle Scholar
  5. Huang TH, Esteller M: Chromatin remodeling in mammary gland differentiation and breast tumorigenesis. Cold Spring Harb Perspect Biol. 2010, 2: a004515-10.1101/cshperspect.a004515.PubMedPubMed CentralGoogle Scholar
  6. Clevers H: The cancer stem cell: premises, promises and challenges. Nat Med. 2011, 17: 313-319. 10.1038/nsmb.1756.View ArticlePubMedGoogle Scholar
  7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100: 3983-3988. 10.1073/pnas.0530291100.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN, Hung MC: EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell. 2011, 19: 86-100. 10.1016/j.ccr.2010.10.035.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 2003, 100: 11606-11611. 10.1073/pnas.1933744100.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Zeidler M, Varambally S, Cao Q, Chinnaiyan AM, Ferguson DO, Merajver SD, Kleer CG: The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia. 2005, 7: 1011-1019. 10.1593/neo.05472.View ArticlePubMedPubMed CentralGoogle Scholar
  11. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006, 66: 8109-8115. 10.1158/0008-5472.CAN-06-0140.View ArticlePubMedGoogle Scholar
  12. Negrini S, Gorgoulis VG, Halazonetis TD: Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010, 11: 220-228. 10.1038/nrm2858.View ArticlePubMedGoogle Scholar
  13. Esteller M: Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer. 2000, 36: 2294-2300. 10.1016/S0959-8049(00)00303-8.View ArticlePubMedGoogle Scholar
  14. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000, 92: 564-569. 10.1093/jnci/92.7.564.View ArticlePubMedGoogle Scholar
  15. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfj ord JE: Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 2006, 8: R38-10.1186/bcr1522.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Murphy CG, Moynahan ME: BRCA gene structure and function in tumor suppression: a repair-centric perspective. Cancer J. 2010, 16: 39-47. 10.1097/PPO.0b013e3181cf0204.View ArticlePubMedGoogle Scholar
  17. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, kConFab, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ: Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009, 15: 907-913. 10.1038/nm.2000.View ArticlePubMedGoogle Scholar

Copyright

© BioMed Central Ltd 2011

Advertisement